# Absorption and Excretion of Oral Docetaxel

> **NCT05242926** · PHASE1 · WITHDRAWN · sponsor: **Modra Pharmaceuticals**

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** ModraDoc006/r

## Key facts

- **NCT ID:** NCT05242926
- **Lead sponsor:** Modra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-10
- **Primary completion:** 2018-04
- **Final completion:** 2018-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pending further development
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242926, "Absorption and Excretion of Oral Docetaxel". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05242926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*